NightHawk Biosciences Provides Q3 2023 Business Update Nov 20, 2023 04:05PM
NightHawk Biosciences Provides 2022 Year End Business Update Mar 31, 2023 04:05PM
NightHawk Biosciences Provides Third Quarter 2022 Business Update Nov 14, 2022 04:01PM
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility Oct 21, 2022 08:00AM
NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory Aug 23, 2022 07:30AM


Aug 10, 2022 04:05PM NightHawk Biosciences Provides Second Quarter 2022 Business Update
Jun 13, 2022 08:00AM NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
May 16, 2022 04:44PM NightHawk Biosciences Provides First Quarter 2022 Business Update
May 10, 2022 08:00AM NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
May 3, 2022 07:00AM Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
Apr 27, 2022 08:00AM Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
Apr 20, 2022 08:00AM Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
Apr 19, 2022 11:00AM Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities